SKB264-Ⅱ-08: what clinicians are saying
sacituzumab tirumotecan in advanced solid tumors · NCT05631262 ↗ · Phase 2 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Some cited clinicians read SKB264-Ⅱ-08 favorably for tumour-response gains, while a medical oncologist rejects its characterization as registrational, citing docetaxel’s performance. A different medical oncologist combines a favorable benefit–risk reading with questions about prioritizing tumour response. Their interpretation remains qualified by immature survival data and a call for evidence beyond China.
Created with AI · how we check it
- edition 1
- commentary checked Nov 19, 2026
- 62 verified statements
This edition $750, with MCP access for your AI agent. Get this report
8 findings, and what sits behind each
01. Primary ORR: some clinicians question it; some doubt registrational framing
4 of the report's 7 cited clinicians · 15 statements from 4 speakers in 4 sources · 8 passages
Limitations recorded: 3.
Draws on: Design and conduct, Primary endpoint: Objective Response Rate (ORR), Secondary endpoints, The comparison, Population and setting, Primary endpoint: Incidence and severity of adverse events (AEs), Safety and tolerability.
02. Sacituzumab tirumotecan: where clinicians split on confidence in its benefit
5 of the report's 7 cited clinicians · 11 statements from 5 speakers in 5 sources · 7 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Objective Response Rate (ORR), Secondary endpoints, Population and setting, The comparison, Design and conduct, Primary endpoint: Incidence and severity of adverse events (AEs), Safety and tolerability.
03. OS interpretation: a clinician stresses immaturity and crossover despite ORR/PFS gains
2 of the report's 7 cited clinicians · 8 statements from 2 speakers in 4 sources · 8 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Objective Response Rate (ORR), Secondary endpoints, The comparison, Population and setting, Primary endpoint: Incidence and severity of adverse events (AEs), Safety and tolerability, Design and conduct.
04. Safety: a clinician notes fewer grade ≥3 AEs; most flag specific toxicities
3 of the report's 7 cited clinicians · 13 statements from 3 speakers in 4 sources · 7 passages
Limitations recorded: 4.
Draws on: Primary endpoint: Incidence and severity of adverse events (AEs), The comparison, Safety and tolerability, Primary endpoint: Objective Response Rate (ORR), Secondary endpoints, Population and setting, Design and conduct.
05. TROP2 IHC: where clinicians split on its predictive role
2 of the report's 7 cited clinicians · 3 statements from 2 speakers in 3 sources · 3 passages
Limitations recorded: 2.
06. Sacituzumab tirumotecan: a clinician calls for global data despite its China licence
1 of the report's 7 cited clinicians · 4 statements from 1 speaker in 2 sources · 2 passages
Limitations recorded: 2.
Draws on: Population and setting, Primary endpoint: Objective Response Rate (ORR), Primary endpoint: Incidence and severity of adverse events (AEs), Secondary endpoints, The comparison, Safety and tolerability.
07. Spain: a speaker notes delays; a clinician tentatively suggests trials
1 of the report's 7 cited clinicians · 2 statements from 2 speakers in 1 source · 2 passages
Limitations recorded: 2.
08. Activity range: what speakers see; a clinician flags small N and scant CNS data
1 of the report's 7 cited clinicians · 6 statements from 2 speakers in 3 sources · 4 passages
Limitations recorded: 4.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 8
4 of the report's 7 cited clinicians
Primary ORR: some clinicians question it; some doubt registrational framing
15 statements from 4 speakers in 4 sources
2 of the 4 named speakers in this finding hold this view, each a confirmed clinician; 2 of the 4 hold its caveat, “some doubt registrational framing”
- 15
- statements
- 8
- passages
- 4
- sources
- 4
- speakers
What the statements areViews 8Questions and uncertainty 4Clinical experience 0Comparisons 0Restated results and context 3Statement-to-passage links (a passage can back several statements)Supporting a statement 16Giving context 0Recorded with the findingLimitations: 3
3 posts and articles · 1 publication
Draws on: Design and conduct, Primary endpoint: Objective Response Rate (ORR), Secondary endpoints, The comparison, Population and setting, Primary endpoint: Incidence and severity of adverse events (AEs), Safety and tolerability.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
Abbreviations (11)
ADC, antibody–drug conjugate; AE, adverse event; CNS, central nervous system; EGFR, epidermal growth factor receptor; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
The full SKB264-Ⅱ-08 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say would resolve concerns about OptiTROP-Lung03’s ORR primary endpoint and PFS reliability for sac-TMT versus docetaxel in advanced EGFR-mutated NSCLC after EGFR-TKI and platinum chemotherapy?
From finding F1 (15 statements from 4 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 19commentary sources screened
- 10sources cited by verified statements
- 9named in screened sources
- 9speakers cited in the report
- 8cited speakers with a verified identity
7 cited clinicians, speakers with a confirmed clinical role, of them 7 physicians. By role and specialty:
- 4 physician, Medical oncology
- 3 physician, specialty not confirmed
Also in the sources: 1 organizational or shared account, not counted as people.
- 62verified statements, each linked to its source
- 21of them from speakers with a confirmed clinical role
- 8findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 62 | Paid |
| Who said each statement: the cited speakers | 9 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 8 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 10 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
12 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Objective Response Rate (ORR) | 9 | 6 |
| Primary endpoint: Incidence and severity of adverse events (AEs) | 5 | 3 |
| Secondary endpoints | 8 | 5 |
| Population and setting | 8 | 6 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 9 | 5 |
| Safety and tolerability | 5 | 3 |
| Design and conduct | 9 | 3 |
| TROP2 IHC, selection and development-program expectations | 2 | 2 |
| Global applicability and reported Chinese licensing | 1 | 1 |
| Spanish access and possible research participation | 2 | 1 |
| Whether benefit will hold in light of experience with other TROP2 ADCs | 1 | 1 |
| Broader actionable-alteration cohorts, CNS evidence and next-study expectations | 5 | 2 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
62 verified statements from 10 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Posts · 26 statements · 42% | ||||
| X threads | 26 | 8 | 16 | |
| Bluesky threads | 0 | 0 | 3 | |
| Primary sources · 36 statements · 58%cited for context, not screened | ||||
| Publications | 36 | 2 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 11 / quarter
- Screened window
- Apr 13, 2025 → Sep 14, 2026
- Cited window
- Jun 1, 2025 → Sep 14, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
- Registry
- NCT05631262
- Study IDs
- SKB264-Ⅱ-08
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Design
- Phase 2 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 321 actual
- Registered
- 2022-11-30
- Start
- 2022-11-30 actual
- Primary completion
- 2026-12-30 estimated
- Primary endpoints
- Objective Response Rate (ORR)
- Incidence and severity of adverse events (AEs)
- Interventions
- 2 registered
More on: Advanced solid tumors, sacituzumab tirumotecan
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 52 sources about other trials or topics are not included.
- Discussion may be missing when a source used an unnamed reference, a different spelling or another way of describing the study. The report should not be read as exhaustive public sentiment.
- Public X reactions, presenter relays and publication summaries do not establish independent clinician counts, consensus, prescribing behavior or patient outcomes in routine care.
Show all 9 known gaps +Fewer −
- A separate protocol and an exact SKB264 regulatory label were not available among the documents reviewed. Regulatory-endpoint and licensing statements therefore remain attributed accounts rather than independently confirmed requirements or indications.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The June 2025 randomized-comparison discussion and the September 2026 molecularly broader posts address different settings. Post dates and meeting hashtags do not establish session dates or changes in opinion.
- Some reported descriptions differ, including phase 2 versus phase 3 labeling and OS hazard ratios. The report preserves those differences rather than creating a reconciled estimate.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 19, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. SKB264-Ⅱ-08 (NCT05631262): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/skb264-08-nct05631262
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "SKB264-Ⅱ-08" (NCT05631262), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "skb264-08-nct05631262". If you cannot make requests, read https://www.erudio.com/reports/skb264-08-nct05631262.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05631262", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05631262 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/skb264-08-nct05631262.json
curl https://www.erudio.com/reports/skb264-08-nct05631262.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "skb264-08-nct05631262" })release ec8465801654378542bd8a6e6a7938f24359b2536ff4ee8000c655e82e0557ef
Questions
How much does the SKB264-Ⅱ-08 report cost?
One edition costs $750 (Focused · 62 verified statements · 21 from 7 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the SKB264-Ⅱ-08 report cover?
62 statements from 10 sources (8 posts, 2 papers), 21 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the SKB264-Ⅱ-08 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "skb264-08-nct05631262" }) previews it and create_order({ "report": "skb264-08-nct05631262", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the SKB264-Ⅱ-08 report?
Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.